Is There a Link Between Pharmaceutical Consumption and Improved Health in OECD Countries?*

The Determination of the Factors Affecting Pharmaceutical Consumption in Respect to Provinces in Turkey

“…In some studies, the factors affecting the amount of the sale of medicine prescribed by medical doctors in Iran with panel data analysis (Tahmasebi et al, 2013), the relation between health care services and pharmaceutical consumption in seven European countries (Grandfils et al, 2009), the relation between pharmaceutical consumption and life expectancy by using the data of OECD countries (Miller and French, 2000;Frech and Richard, 2004;Shaw et al, 2005;Caliskan, 2009), the reasons of increasing pharmaceutical expenses in Greece between 1991 and 2006 (Lambrelli and O'Donnell, 2011), the relation between general health results and pharmaceutical expenses in Canada (Crémieux et al, 2004) and the effect and importance of the determinants of health expenses per person (Karatzas, 2000;Fukawa and Izumida, 2004) have been examined.…”

“…It has been determined in some studies that there is a positive relation between life expectancy and pharmaceutical consumption (Grandfils et al, 2009;Miller and French, 2000;Shaw et al, 2005;Frech and Richard, 2004;Caliskan, 2009). Life expectancies of male and female at birth have been taken as separate variables in this study.…”

Empirical Evidence on the Value of Pharmaceuticals

“…Several studies have attempted to examine the impact of pharmaceuticals on society. Miller and Frech (2000) examined the effect of pharmaceutical spending on life expectancy. Using OECD data, the authors estimated the effect of a variety of factors, including prescription medications, on life expectancy at birth, 40 years of age, and 60 years of age.…”

Accuracy in Pharmacoeconomic Literature Review: Lessons Learned From the Navajo Code Talkers

“…8 Consistent with Schulz and Lewis's concerns, examination of a convenience sample of these publications reveals numerous serious errors in describing the study's results (Table 2). [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] The most common and serious error was attributing inpatient hospitalizations to the cap although Soumerai et al found no significant relationship between the cap and hospital admission rates. 9,[11][12][13]19,21,23 Additional errors occurred when describing the cap itself, which was commonly represented as a formulary.…”

“…9,[11][12][13]19,21,23 Additional errors occurred when describing the cap itself, which was commonly represented as a formulary. 12,16,[19][20][21] Similarly, one description of the paper attributed negative outcomes to copayments despite Soumerai et al's finding that the risk of nursing home admission returned to its baseline (pre-cap) level when the cap was replaced by a $1 copayment. 5,15 Notably, some discussions of the work cited outcomes that were not even studied by Soumerai et al; these included changes in physician practice patterns, prescribing rates, emergency room use, and even mortality.…”